Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 16/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 15/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 14/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986091 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28204791 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29376980 | 0.79 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20487358 | 0.78 | — | — | |
| SCHEMBL1366389 | 0.78 | — | — | |
| SCHEMBL14898986 | 0.78 | — | — | |
| SCHEMBL2984779 | 0.78 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31170446 | 0.77 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28205359 | 0.77 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2990754 | 0.77 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-107849047-B | Biphenyl derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-107849047-A | Biphenyl derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192703-A1 | Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof | CDK9, CDK8, CDK19 | CHRNB2 4882/4885CHRNA4 4837/4885CHRNB4 4868/4885 |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | CHRNB2 1/4885CHRNA4 3/4885CHRNB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.